How Pieces Technologies’ AI is Driving Clinical Efficiency

By Michael Awood

September 14, 2023

Significant progress is being made in healthcare by Pieces Technologies Inc.

Healthcare professionals use its Artificial Intelligence (AI) platform to manage cases, plan discharges, and reduce hospital stays. Recently, the AI wrote its one-millionth clinical summary – in just seven months. This displays the role and impact that AI can have in healthcare.

The Pieces system uses advanced technology and human help to ensure high accuracy while maintaining a hallucination rate of less than 0.1%. “Hallucinations” refer to instances where the AI produces incorrect or nonsensical outputs. However, Pieces shows great promise in this area with a considerable improvement compared to existing models. This high accuracy is further evidenced by the reduced need for edits in the system’s output.

The software is a trusted tool for healthcare professionals, supporting various clinical procedures and contributing to efforts aimed at reducing patient stay duration and readmission rates.
This achievement highlights the potential of applied clinical generative AI in healthcare delivery. Pieces Technologies has committed to safety, transparency, and accountability to improve healthcare outcomes and operations.

Pieces Technologies is leading the way in redefining healthcare through AI, achieving clinical efficiency and patient care. The system is set to be implemented in pediatric hospital environments soon, further expanding its impact. This highlights the importance of AI in healthcare, not to surpass benchmarks, but to enhance patient care and clinical outcomes.

 

Cover image source: PR Newswire. Link in the reference URL

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This